Overview

This trial is active, not recruiting.

Condition coronary artery disease
Treatment myocardial perfusion imaging using rb-82 pet or tc-99m or tl spect
Sponsor Ottawa Heart Institute Research Corporation
Collaborator Canadian Institutes of Health Research (CIHR)
Start date April 2010
End date June 2017
Trial size 10000 participants
Trial identifier NCT01128023, 211897

Summary

Cardiovascular (CV) disease is the leading cause of death in Canada. Fifty percent of all Tc-99m used in nuclear medicine is for the diagnosis of coronary artery disease (CAD) with SPECT myocardial perfusion imaging (MPI). The reduced supply of Tc-99m requires other tracers to be investigated. Tl-201 SPECT is available but generally accepted to be inferior to Tc-99m. Rubidium (Rb-82), a nonreactor produced tracer, is believed to have superior accuracy compared to Tc-99m and Tl-201 SPECT, with 5-20 times lower radiation dose. In the U.S. Rb-82 generators have been FDA-approved since 1989 and are used increasingly for CAD diagnosis, but are still considered investigational in Canada.

Objectives: To demonstrate that Rb-82 PET MPI is i) an accurate, cost-effective alternative to Tc-99m; ii) superior to Tl-201; iii) can be implemented in multiple Canadian centres for the diagnosis and management of CAD. Short term clinical outcomes of Rb-82 will be evaluated and compared to Tc-99m and Tl-201 SPECT MPI across Canadian imaging centres.

Plan: Rb-ARMI is an innovative multidisciplinary, multi-centre imaging research initiative that builds on existing collaborative networks and Canadian industry partnership (DRAXIMAGE). Rb PET will be implemented, standardized and validated in 4 overlapping phases over 2 years, at 10 Canadian Centres.

Impact: This project meets the expected goal to "lead to clinical trial applications and clinical validation studies which compare novel radiolabeled probes with those in current practice", and to "bring a new radiopharmaceutical to the clinic" within a short time frame. Increased use of Rb-82 PET MPI has the potential to reduce the demand for Tc-99m by 10-40%, effectively increasing the available supply for other procedures, and improving the standard of care for many Canadians at risk of heart disease.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Patients diagnosed with or suspected coronary artery disease requiring evaluation and/or risk stratification will undergo PET Rb-82 perfusion imaging.
myocardial perfusion imaging using rb-82 pet or tc-99m or tl spect
Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
Patients diagnosed with or suspected coronary artery disease who have undergone SPECT myocardial perfusion imaging.
myocardial perfusion imaging using rb-82 pet or tc-99m or tl spect
Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.

Primary Outcomes

Measure
The accuracy of rubidium-82 PET MPI for the diagnosis of CAD will be compared to Tc-99m and Tl-201 SPECT.
time frame: Baseline

Secondary Outcomes

Measure
Evaluate the short-term resource utilization, costs and cost-effectiveness of rubidium-82 PET MPI for diagnosis and management of patients evaluated for CAD, compared to Tc-99m and Tl-201 SPECT
time frame: 6 months
To evaluate the short-term clinical outcomes of rubidium-82 PET MPI for diagnosis and management of CAD, compared to Tc-99m and Tl-201 SPECT
time frame: 6 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - patients referred for myocardial perfusion imaging for diagnosis and/or risk stratification for CAD - male or female - 18 years of age or older - having given informed consent Exclusion Criteria: - contraindications to dipyridamole radionuclide imaging including - severe reactive airway disease - <3 days post MI/acute coronary syndrome (ACS) presentation - unstable crescendo angina - high grade atrio-ventricular (AV) block - allergy to dipyridamole or theophyllines - caffeine within 24 hours - theophyllines within 48 hours - severe claustrophobia - patients who may be pregnant

Additional Information

Official title Rubidium-82 - An Alternative Radiopharmaceutical for Myocardial Imaging(Rb-ARMI)
Principal investigator Rob S Beanlands, MD
Description Rationale: Cardiovascular (CV) disease is the leading cause of death in Canada. Half of all the Tc-99m used in nuclear medicine is for the diagnosis of coronary artery disease (CAD) with SPECT myocardial perfusion imaging (MPI). The reduced supply of Tc-99m requires other tracers to be investigated. While Tl-201 SPECT is available, it is generally accepted to be inferior to the Tc-99m tracers; low specificity may prompt further testing and increase costs. Rubidium (Rb-82) PET MPI is believed to have superior accuracy compared to Tc-99m and Tl-201, and 5-20 times lower radiation dose. Rb-82 is produced in a generator from the cyclotron-produced (non-reactor) parent isotope Sr-82. In the U.S. Rb-82 generators have been FDA-approved since 1989. Rb-82 PET MPI has been reimbursed in the U.S. since 1995 and is used increasingly for CAD diagnosis, but is still considered investigational in Canada. Objectives: Primary: To demonstrate that Rb-82 PET MPI is i) an accurate alternative to Tc-99m SPECT;ii) is superior to Tl-201; iii) can be implemented in multiple Canadian centres for diagnosis and management of CAD. Secondary: To evaluate short-term clinical outcomes and cost-effectiveness of Rb-82 PET MPI for diagnosis and management of CAD compared i) to Tc-99m and Tl-201 MPI and ii) across imaging centres. Hypotheses: 1: Rubidium MPI can be standardized with highly repeatable interpretation across multiple Canadian centres, using current 3D PET and 3D PET/CT imaging technology. 2-A: Rubidium PET MPI has superior accuracy compared to Tl-201 SPECT MPI, using invasive coronary angiography (ICA) as the gold-standard for diagnosis of CAD. (reference centre A - Ottawa) 2-B: Rubidium PET MPI has comparable accuracy to Tc-99m SPECT MPI. (reference centre B - Quebec) 3: Rubidium PET MPI has similar (non-inferior) accuracy across additional Canadian imaging centres compared to the primary imaging centres 4-A: Rubidium PET MPI is cost-effective compared to Tc-99m and Tl-201 SPECT MPI in the diagnosis and management of CAD, in terms of tracer costs and down-stream resource utilization such as ICA. 4-B: Rubidium PET MPI improves short-term clinical outcomes measured at 6 months, compared to Tc-99m or Tl-201 SPECT MPI in the management of CAD, in terms of adverse cardiac events including cardiac death, nonfatal MI, late revascularization and cardiac hospitalization. 4-C: Site-specific attributes will impact resource utilization and local Rb-82 PET costs. Research Plan: Rb-ARMI is an innovative multidisciplinary, multi-centre imaging research initiative that builds on existing collaborative networks (ICT, IMAGE-HF, CAIN, CADRE) and Canadian industry partnership (DRAXIMAGE). Rb-82 PET will be implemented, standardized and validated in 4 overlapping phases over 2 years, in up to 10 centres across Canada, including Ottawa, Quebec City, Montreal, Sherbrooke, Toronto, Hamilton, London, Thunder Bay, Halifax, and Edmonton. Phase 1 is a knowledge translation and standardization phase (0-6 months). Qualifying scans using cardiac phantoms will be performed to standardize imaging protocols across centres. Site training and co-reading of an initial series of scans from each centre will be performed by the reference site (Ottawa), to confirm low inter-operator variability (≤5%) in interpretation (sum stress score and sum difference score). Phase 2 is a matched-cohort comparative accuracy study (months 3-20). In the reference centres, pre-test likelihood ± extent of CAD will be assessed in patients referred for assessment of ischemia (N=200) undergoing dipyridamole Rb-82 PET MPI and coronary angiography (ICA) within 6 months. These patients will be used to identify a matched group undergoing Tl-201 SPECT to compare accuracy in 2A. A similar study will be performed to compare Rb-82 PET with Tc-99m SPECT MPI in centre B (the site most ready to start Rb-82 PET MPI) using the same propensity-matched cohort design in 2B. All 800 angiography studies (+600 in phase 3) will be co-read by the core lab in Montreal. Phase 3 tests whether the implementation of Rb-82 PET across the additional imaging centres in Canada can achieve comparable accuracy, again using ICA as the gold-standard in N=600 patients (months 4-20). Phase 4 is a cost-effectiveness study to evaluate short-term resource utilization (RU), cost and outcomes at 6-month follow-up for: Rb-82 PET vs SPECT MPI (centres A and B) in 4A and 4B (N=1000); Rb-82 PET in additional Canadian sites vs the primary centres in 4C (N=1000). RU will be measured during follow up and unit costs estimated. Analysis will estimate incremental costs associated with each of the outcomes within the composite endpoint, as well as costs associated specifically with the imaging and subsequent diagnostic tests. Cost-effectiveness analysis will be undertaken in accordance with Canadian guidelines for economic evaluations. Database review, follow-up completion, data analysis and manuscript preparation will be completed in the final 6 months of the study. Impact: The project meets the expected goal of the RFA to "lead to clinical trial applications and clinical validation studies which compare novel radiolabeled probes with those in current practice", and to "bring a new radiopharmaceutical to the clinic" within a short time frame. Increased use of Rb-82 PET MPI has the potential to reduce the demand for Tc-99m by 10-40%, effectively increasing the available supply for other procedures, and improving the standard of care for many Canadians at risk of heart disease.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Ottawa Heart Institute Research Corporation.